Xeris Pharmaceuticals Inc (XERS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.04B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xeris Pharmaceuticals Inc (XERS) Stock Forecast
Analysts expect Xeris Pharmaceuticals (XERS) to earn -$0.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $401.51M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 5 | 71.4% |
| Hold | 1 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 31.2%.
- Fiscal year ending Dec 31, 2026
- -$0.01
- EPS consensus, revenue $401.51M
- Fiscal year ending Dec 31, 2027
- $0.27
- EPS consensus, revenue $526.63M
- Next report
- Mar 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.01 | -$0.04 to $0.03 | 3 | $401.51M | $399.60M to $403.95M | 6 |
| Dec 31, 2027 | $0.27 | $0.13 to $0.38 | 3 | $526.63M | $475.80M to $553.50M | 6 |
Quarterly Estimates
The EPS consensus falls from $0.04 for the quarter ending Dec 31, 2026 to $0.03 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.04 | $0.00 to $0.06 | 9 | $120.99M | $114.76M to $127.58M | 8 |
| Mar 31, 2027 | $0.03 | $0.02 to $0.04 | 2 | $115.93M | $114.10M to $118.70M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.01 | -$0.09 | -$0.09 | -$0.08 | -$0.05 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.27 | $0.20 | $0.20 | $0.22 | $0.27 | -1.2% |
| Quarter ending Mar 31, 2027 | $0.03 | $0.03 | $0.03 | $0.04 | $0.04 | -14.3% |
Frequently Asked Questions About XERS
What is the XERS stock forecast?
Consensus analyst estimates put Xeris Pharmaceuticals's EPS at -$0.01 for the fiscal year ending Dec 31, 2026, on revenue of $401.51M. The consensus rating from 7 analysts is Buy.
How do analysts rate XERS stock?
Of 7 analysts covering Xeris Pharmaceuticals, 1 rates it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from XERS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.01, with estimates from -$0.04 to $0.03 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.27, with estimates from $0.13 to $0.38 from 3 analysts.
What revenue do analysts expect from Xeris Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $401.51M, with estimates from $399.60M to $403.95M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $526.63M, with estimates from $475.80M to $553.50M.
How many analysts cover XERS?
7 analysts rate Xeris Pharmaceuticals stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
XERS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors